scispace - formally typeset
X

Xingcong Ren

Researcher at Penn State Cancer Institute

Publications -  51
Citations -  7660

Xingcong Ren is an academic researcher from Penn State Cancer Institute. The author has contributed to research in topics: Autophagy & Medicine. The author has an hindex of 26, co-authored 41 publications receiving 6914 citations. Previous affiliations of Xingcong Ren include Rutgers University & Penn State Milton S. Hershey Medical Center.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells

Hua Zhu, +7 more
- 16 Aug 2009 - 
TL;DR: It is reported here that microRNAs (miRNAs), a class of endogenous, 22–24 nucleotide noncoding RNA molecules able to affect stability and translation of mRNA, may represent a previously unrecognized mechanism for regulating beclin 1 expression and autophagy.
Journal ArticleDOI

Therapeutic Targeting of Autophagy in Disease: Biology and Pharmacology

Yan Cheng, +3 more
- 01 Oct 2013 - 
TL;DR: A better understanding of the biology of Autophagy and the pharmacology of autophagy modulators has the potential for facilitating the development ofAutophagy-based therapeutic interventions for several human diseases.
Journal ArticleDOI

eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206

Yan Cheng, +10 more
- 01 Apr 2011 - 
TL;DR: Regulatory mechanisms through which apoptosis and autophagy were modulated in tumor cells subjected to Akt inhibition by MK-2206 are investigated, suggesting that targeting eEF-2 kinase may reinforce the antitumor efficacy of Akt inhibitors such as MK- 2206.
Journal ArticleDOI

MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis

Yan Cheng, +12 more
- 01 Jan 2012 - 
TL;DR: It is reported here that MK-2206, a potent allosteric Akt inhibitor currently in phase I trials in patients with solid tumors, could reinforce the cytocidal effect of gefitinib against glioma and the combination of these two drugs may be utilized as a new therapeutic regimen for malignantglioma.